Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial

Abstract Objectives To assess the effect of montelukast versus salmeterol added to inhaled fluticasone propionate on asthma exacerbation in patients whose symptoms are inadequately controlled with fluticasone alone. Design and setting A 52 week, two period, double blind, multicentre trial during which patients whose symptoms remained uncontrolled by inhaled corticosteroids were randomised to add montelukast or salmeterol. Participants Patients (15-72 years; n = 1490) had a clinical history of chronic asthma for ≥ 1 year, a baseline forced expiratory volume in one second (FEV 1) value 50-90% predicted, and a β agonist improvement of ≥ 12% in FEV 1. Main outcome measures The primary end point was the percentage of patients with at least one asthma exacerbation. Results 20.1% of the patients in the group receiving montelukast and fluticasone had an asthma exacerbation compared with 19.1% in the group receiving salmeterol and fluticasone; the difference was 1% (95% confidence interval -3.1% to 5.0%). With a risk ratio (montelukast-fluticasone/salmeterol-fluticasone) of 1.05 (0.86 to 1.29), treatment with montelukast and fluticasone was shown to be non-inferior to treatment with salmeterol and fluticasone. Salmeterol and fluticasone significantly increased FEV 1 before a β agonist was used and morning peak expiratory flow compared with montelukast and fluticasone (P ≤ 0.001), whereas FEV 1 after a β agonist was used and improvements in asthma specific quality of life and nocturnal awakenings were similar between the groups. Montelukast and fluticasone significantly (P = 0.011) reduced peripheral blood eosinophil counts compared with salmeterol and fluticasone. Both treatments were generally well tolerated. Conclusion The addition of montelukast in patients whose symptoms remain uncontrolled by inhaled fluticasone could provide equivalent clinical control to salmeterol.

[1]  A. Buist.  Guidelines for the management of chronic obstructive pulmonary disease. , 2002, Respiratory medicine.

[2]  M. Adachi,et al.  Reduction of eosinophilic inflammation in the airways of patients with asthma using montelukast. , 2002, Chest.

[3]  P. Barnes,et al.  Clinical outcome of adding long-acting β-agonists to inhaled corticosteroids , 2001 .

[4]  S. Yancey,et al.  Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy. , 2001, Chest.

[5]  W. Craig.  Re-evaluating current antibiotic therapy , 2001 .

[6]  R. Martin,et al.  Distal lung dysfunction at night in nocturnal asthma. , 2001, American journal of respiratory and critical care medicine.

[7]  V. Brusasco,et al.  Allergic inflammation and airway smooth muscle function. , 2001, The Science of the total environment.

[8]  B. Lipworth,et al.  Evaluation of salmeterol or montelukast as second-line therapy for asthma not controlled with inhaled corticosteroids. , 2001, Chest.

[9]  A. Knox,et al.  Regulation of TNF‐α‐induced eotaxin release from cultured human airway smooth muscle cells by β2‐agonists and corticosteroids , 2001 .

[10]  T. Haahtela,et al.  Granulocyte markers in induced sputum in patients with respiratory disorders and healthy persons obtained by two sputum-processing methods. , 2001, Respiratory medicine.

[11]  P. Barnes.  Clinical outcome of adding long-acting beta-agonists to inhaled corticosteroids. , 2001, Respiratory medicine.

[12]  A. Knox,et al.  Regulation of TNF-alpha-induced eotaxin release from cultured human airway smooth muscle cells by beta2-agonists and corticosteroids. , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[13]  E. Kerwin,et al.  Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. , 2000, The Journal of allergy and clinical immunology.

[14]  A. Bush,et al.  Effect of oral glucocorticoid treatment on serum inflammatory markers in acute asthma , 2000, Archives of disease in childhood.

[15]  D. Stempel.  Montelukast added to inhaled beclomethasone in treatment of asthma. , 2000, American journal of respiratory and critical care medicine.

[16]  S. Shrewsbury,et al.  Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA) , 2000, BMJ : British Medical Journal.

[17]  A. Markham,et al.  Montelukast: a review of its therapeutic potential in persistent asthma. , 2000, Drugs.

[18]  H. Bisgaard.  Long‐acting β2‐agonists in management of childhood asthma: A critical review of the literature , 2000 .

[19]  H. Bisgaard.  Long-acting beta(2)-agonists in management of childhood asthma: A critical review of the literature. , 2000, Pediatric pulmonology.

[20]  M. Laviolette,et al.  Montelukast added to inhaled beclomethasone in treatment of asthma. Montelukast/Beclomethasone Additivity Group. , 1999, American journal of respiratory and critical care medicine.

[21]  E. Israel,et al.  Treatment of asthma with drugs modifying the leukotriene pathway. , 1999, The New England journal of medicine.

[22]  A. Chuchalin,et al.  Montelukast versus salmeterol in patients with asthma and exercise-induced bronchoconstriction. Montelukast/Salmeterol Exercise Study Group. , 1999, The Journal of allergy and clinical immunology.

[23]  L. Boulet,et al.  Montelukast reduces airway eosinophilic inflammation in asthma: a randomized, controlled trial. , 1999, The European respiratory journal.

[24]  P. Barnes,et al.  Efficacy of inhaled corticosteroids in asthma. , 1998, The Journal of allergy and clinical immunology.

[25]  W. Busse.  Inflammation in asthma: the cornerstone of the disease and target of therapy. , 1998, The Journal of allergy and clinical immunology.

[26]  R. Kay.  Statistical Principles for Clinical Trials , 1998, The Journal of international medical research.

[27]  J. FitzGerald,et al.  Effect of inhaled formoterol and budesonide on exacerbations of asthma. , 1998, The New England journal of medicine.

[28]  D. Postma,et al.  Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. , 1997, The New England journal of medicine.

[29]  The British Guidelines on Asthma Management1995 Review and Position Statement , 1997 .

[30]  J Zhang,et al.  Effects of montelukast (MK-0476); a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids. , 1997, Thorax.

[31]  A. Woolcock,et al.  Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. , 1996, American journal of respiratory and critical care medicine.

[32]  J. Bousquet,et al.  Eosinophil inflammation in asthma. , 1994, American journal of respiratory and critical care medicine.

[33]  P. Ind,et al.  Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid , 1994, The Lancet.

[34]  A. Sala,et al.  Differential effects of fluticasone propionate on allergen-evoked bronchoconstriction and increased urinary leukotriene E4 excretion. , 1994, American journal of respiratory and critical care medicine.

[35]  N. Baber,et al.  International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use (ICH). , 1994, British journal of clinical pharmacology.

[36]  J. Oates,et al.  Effect of oral prednisone on airway inflammatory mediators in atopic asthma. , 1994, American journal of respiratory and critical care medicine.

[37]  G H Guyatt,et al.  Determining a minimal important change in a disease-specific Quality of Life Questionnaire. , 1994, Journal of clinical epidemiology.

[38]  K. O'Shaughnessy,et al.  Differential effects of fluticasone propionate on allergen-evoked bronchoconstriction and increased urinary leukotriene E4 excretion. , 1993, The American review of respiratory disease.